ECSP13012650A - Métodos y composiciones para tratar diarrea asociada con vih - Google Patents

Métodos y composiciones para tratar diarrea asociada con vih

Info

Publication number
ECSP13012650A
ECSP13012650A ECSP13012650A ECSP13012650A EC SP13012650 A ECSP13012650 A EC SP13012650A EC SP13012650 A ECSP13012650 A EC SP13012650A EC SP13012650 A ECSP13012650 A EC SP13012650A
Authority
EC
Ecuador
Prior art keywords
diarrhea
methods
hiv
compositions
diarrhea associated
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
William Forbes
Enoch Bortey
Steven King
Pravin Chaturvedi
Original Assignee
Salix Pharmaceuticals Ltd
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012650(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salix Pharmaceuticals Ltd, Napo Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Ltd
Publication of ECSP13012650A publication Critical patent/ECSP13012650A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
ECSP13012650 2010-10-31 2013-05-31 Métodos y composiciones para tratar diarrea asociada con vih ECSP13012650A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40862210P 2010-10-31 2010-10-31
US40933510P 2010-11-02 2010-11-02
US41624910P 2010-11-22 2010-11-22
US201161434379P 2011-01-19 2011-01-19

Publications (1)

Publication Number Publication Date
ECSP13012650A true ECSP13012650A (es) 2013-10-31

Family

ID=45994461

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012650 ECSP13012650A (es) 2010-10-31 2013-05-31 Métodos y composiciones para tratar diarrea asociada con vih

Country Status (20)

Country Link
US (4) US8962680B2 (enExample)
EP (1) EP2632550B1 (enExample)
JP (2) JP6063385B2 (enExample)
CN (2) CN103370101A (enExample)
AU (1) AU2011320155B2 (enExample)
BR (1) BR112013010774A2 (enExample)
CA (1) CA2816416C (enExample)
DK (1) DK2632550T3 (enExample)
EC (1) ECSP13012650A (enExample)
ES (1) ES2635435T3 (enExample)
HK (1) HK1249036A1 (enExample)
HU (1) HUE035393T2 (enExample)
MX (1) MX348184B (enExample)
PE (1) PE20140036A1 (enExample)
PH (1) PH12013500857A1 (enExample)
PL (1) PL2632550T3 (enExample)
PT (1) PT2632550T (enExample)
RU (1) RU2597746C2 (enExample)
WO (1) WO2012058664A1 (enExample)
ZA (1) ZA201303136B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535419A (ja) 2006-05-01 2009-10-01 ナポ ファーマシューティカルズ インク． 便秘型過敏性腸症候群の治療方法
US8852649B2 (en) 2006-05-01 2014-10-07 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
BR112013010774A2 (pt) 2010-10-31 2017-03-21 Napo Pharmaceuticals Inc "usos de crofelemer no tratamento de diarreia associada ao hiv"
US20140163096A1 (en) * 2012-12-07 2014-06-12 Pam Golden Methods and compositions for treating hiv-associated diarrhea
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
JP2023538186A (ja) * 2020-06-19 2023-09-07 ナポ ファーマシューティカルズ インク． 化学療法誘発性下痢を治療するための方法及び組成物
WO2022115481A1 (en) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating post-acute infection gastrointestinal disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
EP0935417B1 (en) * 1996-10-16 2009-05-06 Napo Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20040071793A1 (en) 2002-10-05 2004-04-15 Bobrowski Paul J. Oral rehydration methods and compositions
US20080025966A1 (en) * 2004-01-30 2008-01-31 Currie Mark G Methods And Compositions For The Treatment Of Gastrointestinal disorders
CA2667449A1 (en) * 2005-06-22 2007-01-04 University Of Massachusetts Hiv-1 protease inhibitors, and methods of making and using them
JP2009524585A (ja) 2005-12-15 2009-07-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト ウイルス感染を処置するためのジアリールウレア
JP2009535419A (ja) 2006-05-01 2009-10-01 ナポ ファーマシューティカルズ インク． 便秘型過敏性腸症候群の治療方法
US8852649B2 (en) 2006-05-01 2014-10-07 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2010021681A2 (en) 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
EA023814B1 (ru) 2009-08-26 2016-07-29 Гленмарк Фармасьютикалс Лтд. Способ получения полимерных композиций на основе проантоцианидина для фармацевтических форм
AU2010303577B2 (en) 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
US20110087530A1 (en) 2009-10-09 2011-04-14 Visa U.S.A. Inc. Systems and Methods to Provide Loyalty Programs
BR112013010774A2 (pt) 2010-10-31 2017-03-21 Napo Pharmaceuticals Inc "usos de crofelemer no tratamento de diarreia associada ao hiv"
BR112013018688B1 (pt) 2011-01-27 2021-08-24 Napo Pharmaceuticals, Inc Método de produção de uma composição polimérica de proantocianidina
RU2014124981A (ru) 2011-12-22 2016-02-10 Гленмарк Фармасьютикалс Лимитед Неэнтеросолюбильная фармацевтическая композиция, содержащая крофелемер
US20140163096A1 (en) 2012-12-07 2014-06-12 Pam Golden Methods and compositions for treating hiv-associated diarrhea

Also Published As

Publication number Publication date
JP6310971B2 (ja) 2018-04-11
CA2816416C (en) 2020-02-11
AU2011320155A1 (en) 2013-05-09
RU2597746C2 (ru) 2016-09-20
MX348184B (es) 2017-06-02
CN103370101A (zh) 2013-10-23
BR112013010774A2 (pt) 2017-03-21
JP2017019806A (ja) 2017-01-26
ZA201303136B (en) 2016-01-27
EP2632550B1 (en) 2017-05-03
PE20140036A1 (es) 2014-01-31
CN107595836A (zh) 2018-01-19
PL2632550T3 (pl) 2017-10-31
PH12013500857A1 (en) 2018-01-17
US20120107370A1 (en) 2012-05-03
US9585868B2 (en) 2017-03-07
HUE035393T2 (en) 2018-05-02
CA2816416A1 (en) 2012-05-03
AU2011320155B2 (en) 2016-02-25
WO2012058664A1 (en) 2012-05-03
US20120184605A1 (en) 2012-07-19
US8962680B2 (en) 2015-02-24
EP2632550A4 (en) 2014-04-23
MX2013004873A (es) 2013-08-21
PT2632550T (pt) 2017-08-02
EP2632550A1 (en) 2013-09-04
US20150190367A1 (en) 2015-07-09
ES2635435T3 (es) 2017-10-03
DK2632550T3 (en) 2017-08-07
RU2013123794A (ru) 2014-12-10
US20140294903A1 (en) 2014-10-02
HK1249036A1 (zh) 2018-10-26
JP2013540826A (ja) 2013-11-07
JP6063385B2 (ja) 2017-01-18

Similar Documents

Publication Publication Date Title
ECSP13012650A (es) Métodos y composiciones para tratar diarrea asociada con vih
MX382400B (es) Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea.
ECSP15030799A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos
NZ602219A (en) Methods and compositions for treating degos’ disease
ECSP12012106A (es) Terapia antiviral
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.
BR112014019350A8 (pt) Composição terapêutica estéril, seu uso para tratar diarreia induzida por rotavírus e embalagem
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
MX2015007065A (es) Metodo y composiciones para tratar diarrea asociada con vih.
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
CO6670518A2 (es) Tratamiento de infecciones de clostridium difícile en pacientes bajo terapia con antibióticos
MX2014003873A (es) Metodo para tratar el carcinoma mucoepidermoide.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
CO6771411A2 (es) Metodos y composiciones para tratar diarrea asociada al vih
MX2022016367A (es) Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
GT201400071A (es) Combinación terapéutica para el tratamiento de cáncer
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
AR092169A1 (es) Composicion farmaceutica sinergica adaptada para ser administrable oralmente como antiparasitario y procesos para prepararla
CL2022003634A1 (es) Métodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
CL2024003535A1 (es) Métodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia
CR20160116A (es) Método para tratar onicomicosis con hidroxipropil quitasano